about
The risks of overlooking the diagnosis of secreting pituitary adenomasBaseline serum concentrations of zinc, selenium, and prolactin in critically ill childrenUnilateral Galactorrhea Associated with Low-dose EscitalopramProlactin serum levels and breast cancer: relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case-control study from PolandSerum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes?Serum prolactin and macroprolactin levels among outpatients with major depressive disorder following the administration of selective serotonin-reuptake inhibitors: a cross-sectional pilot studyRecommendations on the diagnosis, treatment and monitoring of hypogonadism in men.Hyperprolactinemia Secondary to Allergic Fungal Sinusitis Compressing the Pituitary Gland.Evaluation of serum prolactin levels in intellectually disabled patients using antipsychotic medications.Preclinical risk assessment of drug-induced hypo- and hyperprolactinemia.Drug-induced hypo- and hyperprolactinemia: mechanisms, clinical and therapeutic consequences.Challenges and pitfalls in the diagnosis of hyperprolactinemia.The epidemiology of hyperprolactinaemia over 20 years in the Tayside region of Scotland: the Prolactin Epidemiology, Audit and Research Study (PROLEARS).Acute hormonal findings after aneurysmal subarachnoid hemorrhage - report from a single center.Clinical Management of Antipsychotic-Induced Hyperprolactinemia.Male Reproductive Functions Disrupted by Pharmacological Agents.Hyperprolactinaemia in male infertility: Clinical case scenarios.Different Endocrine Effects of an Evening Dose of Amitriptyline, Escitalopram, and Placebo in Healthy Participants
P2860
Q28076665-AC73257E-6AD5-4136-B346-7203DC468CC4Q30414914-5F4065F3-8DEB-414C-964F-5297671E839EQ33908871-B56E65EE-F03C-4E79-9579-9F5AC6BAD7F2Q34250104-78786A23-E37A-4ACA-A80F-3CDDE5222FD1Q34631033-5AAFBADE-4944-4F54-B57C-4E676561E4D4Q35061572-107FDB16-A0BC-48C2-B38D-7673DF47432EQ36287950-C20DC3BA-FCB7-4D82-953A-405DE1EEF7E3Q36655217-4434EC5B-642D-4D28-B94C-18285C0E566CQ36957445-8B7CCCBB-FA34-431C-A153-687E9E6975BBQ37925692-BDA62C19-B100-414B-8CE0-10B91EE4DCEDQ38100267-3EFC6E43-5C59-4B8F-AF28-981E90566E25Q38204249-4FC36698-23FB-4A22-987A-542B866A0A72Q38406655-3F500BB7-E6A8-492A-9030-62EF18B0461EQ48474125-C5D96773-59B3-4234-AB15-4E951D829DD8Q50593929-5A460792-3E44-4D03-AD07-8E7E83C11C20Q52687141-CF4749EF-5D12-4823-BF19-1625E36E65A7Q55093059-70B5B58B-9CD3-4665-B7EE-972BBEE5DBF0Q58781397-E7A7BF67-7AD2-4E7E-BFCF-2CEDC0118389
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Drugs and prolactin.
@en
Drugs and prolactin.
@nl
type
label
Drugs and prolactin.
@en
Drugs and prolactin.
@nl
prefLabel
Drugs and prolactin.
@en
Drugs and prolactin.
@nl
P2860
P1433
P1476
Drugs and prolactin.
@en
P2093
Mark E Molitch
P2860
P2888
P304
P356
10.1007/S11102-008-0106-6
P577
2008-01-01T00:00:00Z